The nematode
Caenorhabditis elegans
(
C. elegans
) offers a unique opportunity for biological and basic medical researches due to its genetic tractability and well-defined developmental lineage. It also provides an exceptional model for genetic, molecular, and cellular analysis of human disease-related genes. Recently,
C. elegans
has been used as an ideal model for the identification and functional analysis of drugs (or small-molecules)
in vivo
. In this review, we describe conserved oncogenic signaling pathways (Wnt, Notch, and Ras) and their potential roles in the development of cancer stem cells. During
C. elegans
germline development, these signaling pathways regulate multiple cellular processes such as germline stem cell niche specification, germline stem cell maintenance, and germ cell fate specification. Therefore, the aberrant regulations of these signaling pathways can cause either loss of germline stem cells or overproliferation of a specific cell type, resulting in sterility. This sterility phenotype allows us to identify drugs that can modulate the oncogenic signaling pathways directly or indirectly through a high-throughput screening. Current
in vivo
or
in vitro
screening methods are largely focused on the specific core signaling components. However, this phenotype-based screening will identify drugs that possibly target upstream or downstream of core signaling pathways as well as exclude toxic effects. Although phenotype-based drug screening is ideal, the identification of drug targets is a major challenge. We here introduce a new technique, called Drug Affinity Responsive Target Stability (DARTS). This innovative method is able to identify the target of the identified drug. Importantly, signaling pathways and their regulators in
C. elegans
are highly conserved in most vertebrates, including humans. Therefore,
C. elegans
will provide a great opportunity to identify therapeutic drugs and their targets, as well as to understand mechanisms underlying the formation of cancer.
CAENORHABDITIS ELEGANSAS A MODEL SYSTEM
The nematode
Caenorhabditis elegans
(
C. elegans
) is a multicellular organism that has become a popular model for biological and basic medical research. It has also been widely used as a model system to explore fundamental questions in multiple aspects of biology, including evolution, development, cell fate specification, stem cell regulation, tumorigenesis, and aging. The
C. elegans
has also been considered as an ideal model system for live animal high-throughput drug screening, as 1) their tissues are transparent at all developmental stages, 2) tissue-specific fluorescent transgenic markers to study physiological and cellular processes
in vivo
are well established, 3) a large number of mutant strains are available in Caenorhabditis Genetics Center (CGC) [
http://www.cbs.umn.edu/research/resources/cgc
], 4) whole genome sequencing has been completed, 5) they have a short lifespan (2 to 3 weeks) and a strong genetic power, and 6) the aspects of mammalian diseases can be successfully modeled in the
C. elegans
(
O’Reilly ., 2014
).
The
C. elegans
life cycle includes embryogenesis (∼12 h), four larval stages (L1–L4; total of ∼3 days) and adulthood (∼10 days) (
Kimble and Crittenden, 2005
).
C. elegans
exists as either hermaphrodites or males. Wild-type hermaphrodites can produce sperm during larval development (L3–L4) and then switch to oogenesis in adulthood (
Fig. 1A
,
1C
). However, males make sperm continuously throughout their lifespan. In addition, the germline is organized in a simple linear fashion that progresses from germline stem cells at one end to maturing gametes at the other (
Fig. 1B
,
1C
).
C. elegans
germline development is tightly regulated by conserved external signaling pathways, including Wnt, Notch and Ras, (
Fig. 1B
) as well as intrinsic regulators, including gene expression regulators and cell cycle regulators (
Kimble and Crittenden, 2007
). Aberrant control of these signaling pathways can cause the loss of the somatic distal tip cells (DTCs, which function as the germline stem cell niche) and germline stem cells as well as extra DTC formation, uncontrolled germline proliferation, and abnormal germ cell fate specification that are all associated with sterility and germline tumors. Therefore, these features of
C. elegans
germline make it a very suitable organism for the phenotype-based high-throughput screening of drugs that target oncogenic signaling pathways and the identification of therapeutic targets.
ONCOGENIC PATHWAYS: WNT SIGNALING
- Overview of Wnt signaling pathway
The Wnt signaling pathway is critical for many aspects of animal development, including stem cell self-renewal, differentiation, cell fate specification, polarity, and cell migration (
Katoh, 2008
). There are three Wnt signaling pathways: canonical Wnt/β-catenin pathway, non-canonical Wnt/planar cell polarity (PCP) pathway, and non-canonical Wnt/calcium pathway (
James ., 2008
). All three Wnt signaling pathways are activated by the binding of Wnt ligand to Frizzled family receptor. In absence of its ligand, cytoplasmic β-catenin interacts with APC (polyposis coli) and Axin scaffold proteins, and then is phosphorylated by CKIα kinase and GSK3β (Glycogen Synthase Kinase 3β). The phosphorylated β-catenin is then ubiquitinated and degraded by the proteasome (
Fig. 2A
). Therefore, in the canonical pathway, CKIα, GSK3β, APC, and Axin act as negative regulators. Upon activation, the formation of APC/Axin/CKIα/GSK3β destruction complex is inhibited, which stabilizes β-catenin and leads to its localization in the nucleus (
Fig. 2B
). In the nucleus, β-catenin interacts with TCF family transcription factors to activate the expression of target genes such as FGF20, DKK1, WISP1, MYC, and Cyclin D1 (
He ., 1998
;
Pennica ., 1998
;
Tetsu and McCormick, 1999
;
Chamorro ., 2005
) (
Fig. 2B
). Importantly, these target genes have been implicated in the development of multiple types of cancer, including colon, breast, ovarian, and thyroid.
- Wnt signaling and cancer stem cells
Over the past several years, increasing evidence has been found to be in support of the theory of cancer stem cells (sometimes called tumor stem cells or tumor-initiating cells). Cancer cells are heterogeneous, containing abundant proliferative cells (non-cancer stem cells) and rare cancer stem cells. Furthermore, it has been proven that cancer stem cells are similar to normal stem cells in many aspects and exist in multiple cancers such as leukemia, breast cancer, and lung cancer (
Visvader and Lindeman, 2012
). Therefore, specific therapies targeted at cancer stem cells hold a tremendous promise to increase the efficiency and safety of cancer treatment.
The canonical Wnt/β-catenin is critical for the regulation of embryonic stem cells, adult stem cells, and cancer stem cells (
Nusse ., 2008
). In normal stem cells, the self-renewal and differentiation of stem cells are tightly regulated at least in part by Wnt/β-catenin signaling. For example, R-spondin growth factors interact with Leucine-rich repeat-containing G-protein-coupled receptors (Lgr) (
Chen ., 2013
;
Wang ., 2013
). These R-spondin/Lgr complexes and Wnt ligands directly interact with Frizzled receptors on target cells to activate downstream signaling (
Birchmeier, 2011
). This signaling and downstream activation have been found to be important for the self-renewal and differentiation of stem cells and cancer stem cells (
Reya and Clevers, 2005
;
Holland ., 2013
). Notably, Wnt/β-catenin signaling is likely to control mammary gland stem cell maintenance at different stages of development (
Wend ., 2010
;
Holland ., 2013
). Mammary gland stem cells can give rise to ductal, basal/myoepithelial and alveolar components (
Holland ., 2013
). Therefore, aberrant activation of Wnt/β-catenin signaling contributes to the maintenance of cancer stem cells and results in mammary gland tumorigenesis. In addition, Wnt/β-catenin signaling has been implicated in the regulation of stem cells and cancer stem cells in the nervous system, hematopoietic system, skin, and intestine (
Holland ., 2013
). Therefore, the inhibition of Wnt/β-catenin signaling might reduce the capacity of cancer stem cells, which could be of potential therapeutic benefit in treating multiple types of cancer.
- C. eleganscanonical Wnt/β-catenin signaling
Conserved Wnt/β-catenin signaling pathways and core components in
C. elegans
somatic gonads are summarized in
Fig. 2C
, and well described in (
Eisenmann, 2005
). This review focuses chiefly on canonical Wnt/β-catenin signaling that specifies a germline stem cell niche (known as a DTC in
C. elegans
) fate specification in the
C. elegans
gonad (
Fig. 2D
). The DTC functions as the germline stem cell niche, which is essential for germline stem cell maintenance (
Kimble and Crittenden, 2007
). During early larval development, the DTC arises initially from an asymmetric cell division of a somatic gonadal progenitor (SGP) cell (
Fig. 2C
). This division specifies one daughter DTC potential and another non-DTC potential (
Kimble and Crittenden, 2007
;
Byrd ., 2014
). In hermaphrodites, the DTC potential divides asymmetrically once more to differentiate terminally to form the DTC. The DTC fate is specified by divergent Wnt/β-catenin signaling pathways (
Fig. 2C
). The pathway regulating the asymmetric division of precursor cells, Z1 and Z4, involves Frizzled receptors (LIN-17 and MOM-5), Dishevelled proteins (DSH-2 and MIG-5), β-catenin (SYS-1), and TCF transcription factor (POP-1) (
Kimble and Crittenden, 2007
;
Byrd ., 2014
) (
Fig. 2C
). Aberrant regulation of this pathway results in either the loss of DTC fate (
Fig. 2E
) or the generation of extra DTCs by symmetric division (
Fig. 2F
). Importantly, POP-1/TCF and SYS-1/β-catenin directly activate the transcription of
ceh-22
(Nk×2.5 homolog in mammals) in DTC potentials (
Lam ., 2006
) (
Fig. 2C
). CEH-22/Nk×2.5 is necessary for DTC specification (
Lam ., 2006
). Therefore, Wnt/β-catenin signaling and its direct targets (e.g., CEH-22) play an essential role in DTC fate specification in the
C. elegans
gonads (
Fig. 2C
–
2F
).
- Phenotype-based drug screening for Wnt/β-catenin signaling mutants
In
C. elegans
, the DTC functions as a germline stem cell niche, and it employs GLP-1/Notch signaling to promote continued mitotic divisions. The DTC fate is regulated by Wnt/β-catenin signaling and its direct target, CEH-22/Nk×2.5 (
Lam ., 2006
;
Kimble and Crittenden, 2007
). Therefore, weak or no Wnt signaling results in DTC loss and consequently no germline stem cells, which cause either partially or completely sterile (
Fig. 2E
). To visualize DTCs, a molecular marker
lag-2
::GFP reporter gene can be used. This GFP marker is expressed brightly in DTCs (
Fig. 2D
, see green) (
Blelloch and Kimble, 1999
). The
lag-2
is one of
C. elegans
Notch ligands and expressed in the DTC (
Henderson ., 1994
;
Blelloch ., 1999
). Normally, wild-type hermaphrodites have two DTCs (
Byrd and Kimble, 2009
) (
Fig. 2D
). However, loss of POP-1, SYS-1 or CEH-22 eliminates DTC fate (
Fig. 2E
), and ectopic SYS-1 or CEH-22 produces extra DTCs and generates new germline stem cell populations (
Fig. 2F
,
Table 1
) (
Kimble and Crittenden, 2007
;
Byrd ., 2014
). Indeed, the
ceh-22
gene is a direct target of transcriptional activation by POP-1/TCF and SYS-1/β-catenin (
Fig. 2C
) (
Lam ., 2006
) and is expressed in the cells with DTC potential (
Lam ., 2006
). Notably, about 40% of
ceh-22
mutants are missing both DTCs and are completely sterile. 40% of them are missing one of two DTCs and are partially sterile, and 20% of them produce two DTCs and are fertile (
Lam ., 2006
). Amazingly, ectopic expression of ceh-22 gene produces extra DTCs (
Fig. 2F
,
Table 1
) (
Lam ., 2006
). Therefore,
ceh-22
(
q632
) loss-of-function mutant is an attractive allele to identify drugs that can inhibit or activate the Wnt/β-catenin signaling pathway. If a drug inhibits Wnt/β-catenin directly or indirectly, it will enhance DTC loss and produce the sterile phenotype of
ceh-22
mutants (
Fig. 2G
left). By contrast, if the drug activates Wnt/β-catenin signaling, it will retain the fertility of
ceh-22
mutants and will result in two or more DTCs (
Fig. 2G
right). Furthermore, if the drug suppresses the inhibitor of Wnt/β-catenin signaling directly or indirectly, it can activate Wnt/β-catenin signaling and may retain the fertility of
ceh-22
mutants. The DTC fate is also regulated at least in part by cell cycle regulators. Tilmann and Kimble have previously reported that Cyclin D is required for DTC fate specification (
Tilmann and Kimble, 2005
). Moreover, we also found that cell cycle regulators work together with Wnt/β-catenin signaling to specify DTC fate (
Lee ., 2014
). Therefore, it suggests a possibility that the identified drugs can target the cell cycle regulators and/or Wnt/β-catenin signaling. The specificity can be examined by chemical genetics in Wnt/β-catenin mutants or cell cycle mutants. Therefore, diverse
C. elegans
mutants for Wnt/β-catenin signaling will provide a great opportunity to identify drugs that can potentially treat Wnt/β-catenin signaling-associated human diseases such as colon cancer.
ONCOGENIC PATHWAYS: NOTCH SIGNALING
- Overview of Notch signaling
In most multicellular organisms, the Notch signaling pathway is a highly conserved signaling pathway that controls proliferation, differentiation, cell fate specification, and apoptosis (
Artavanis-Tsakonas ., 1999
). Notch and most of its ligands (DSL: Delta/Serrate/LAG-2) are trans-membrane proteins. Notch ligands are expressed in the cells that are adjacent to the Notch expressing cells. In absence of Notch ligand, CSL (CBF1, Suppressor of Hairless, LAG-1) transcription factors are associated with co-repressors (
Fig. 3A
). This complex inhibits the expression of Notch target genes (
Fig. 3A
). Once the Notch interacts with a ligand, an ADAM-family metalloprotease cleaves the outside of Notch receptor (
Fig. 3B
). After this cleavage, γ-secretase cleaves the remaining part of the Notch receptor inside the inner leaflet of the cell membrane (
Fig. 3B
). This releases the intracellular domain of the Notch (NICD), which then translocates to the nucleus (
Fig. 3B
). In the nucleus, the NICD forms a complex with CSL (CBF1, Suppressor of Hairless, LAG-1) transcription factors and mastermind-like protein (MAML-1) to activate the expression of target genes (
Fig. 3B
). Importantly, an aberrant Notch signaling pathway potentially contributes to cancer development in several different ways (
Allenspach ., 2002
) or to loss of the specific cell type (
Liu ., 2010
). Therefore, the Notch signaling pathway represents a novel target for cancer therapeutic intervention and regenerative medicine.
- Notch signaling and cancer stem cells
Aberrant activation of Notch signaling has been detected in a variety of human cancers including pancreatic cancer (
Ristorcelli and Lombardo, 2010
;
Avila and Kissil, 2013
), colon cancer (
Miyamoto and Rosenberg, 2011
), osteosarcoma (
Hughes, 2009
), glioblastoma (
Lino ., 2010
), lung cancer (
Galluzzo and Bocchetta, 2011
), head and neck cancer (
Sun ., 2014
), and breast cancer (
Reedijk, 2012
). Notably, activation mutations of human Notch1 are reported in approximately 50% of T-ALL (acute lymphoblastic leukemia) cases (
Ferrando, 2009
). The role of Notch in stem cell regulations has been thoroughly studied in several model systems to date. Moreover, the role of the Notch signaling in the initiation and maintenance of cancer stem cells has recently become a subject of study in a number of diverse model organisms. For example, Notch signaling is upregulated in pancreatic cancer stem cells (
Abel ., 2014
). Reduction of the Notch signaling by either genetic inhibition (e.g. Hes1 shRNA) or drug treatment (e.g., γ-secretase inhibitor) in pancreatic cancer decreased cancer stem cell population and tumorsphere formation (
Abel ., 2014
). In addition, the inhibition of Notch signaling by treatment with GSI-18 (γ-secretase inhibitor) depleted the stem cell-like subpopulation derived from medulloblastoma cell lines and abolished xenograft formation (
Fan ., 2006
). By contrast, the activation of the Notch signaling pathway with DSL peptide stimulated tumorsphere formation and increased cancer stem cell population (
Abel ., 2014
). Bao
et al
. also reported that Notch-1 activation induced cancer stem cell self-renewal capacity through epithelial-mesenchymal transition (EMT) (
Bao ., 2011
). Therefore, the Notch signaling pathway is important in maintaining cancer stem cell population, and targeting its pathway in cancer has promising therapeutic potential.
- C. elegansNotch signaling
The Notch signaling pathway and its core components in
C. elegans
are highly conserved. The
C. elegans
has two Notch receptors, GLP-1 and LIN-12, which mediate cell-cell interaction during development (
Greenwald, 2005
). Specifically, GLP-1/Notch signaling in the
C. elegans
germline is critical for germline stem cell maintenance and continued mitotic division (
Kimble and Crittenden, 2007
). LIN-12/Notch signaling in the
C. elegans
somatic cells specifies vulva cell fate during early larval stages (
Greenwald, 2005
). When LAG-2 (GLP-1/Notch ligand) is expressed in DTCs (
Fig. 3C
) (
Henderson ., 1994
) and interacts with the GLP-1/Notch receptor, proteolytic cleavage of the GLP-1/Notch receptor follows (
Fig. 3C
). GLP-1/Notch intracellular domain (NICD) is then trans-located from the membrane into the nucleus (
Fig. 3C
). In the nucleus, the NICD forms a tertiary complex with LAG-1/CSL DNA binding protein and LAG-3/SEL-8/Mastermind transcription co-activator to activate the expression of target genes:
fbf-2
(PUF RNA-binding protein) (
Lamont ., 2004
) and
lip-1
(MAPK phosphatase) (
Berset ., 2001
;
Lee ., 2006
),
lst-1
(Nanos-like zinc finger domain-containing protein) (
Yoo ., 2004
;
Kershner ., 2014
), and
sygl-1
(Novel protein) (
Kershner ., 2014
) (
Fig. 3C
). Importantly, FBF-2, and LIP-1 inhibit meiosis-promoting regulators (e.g., GLD-1, GLD-2, GLD-3, and MPK-1) in the
C. elegans
germline (
Yoo ., 2004
;
Lee ., 2006
;
Kimble and Crittenden, 2007
;
Lee ., 2007a
). Therefore, loss of GLP-1/Notch signaling in germ-line causes a severe proliferation defect during early meiotic entry, resulting in no germline stem cell maintenance and sterility (
Fig. 3D
) (
Austin and Kimble, 1987
), while constitutive activation of this signaling promotes proliferation of germline stem cells and their progenitor cells as well as inhibits entry into meiosis, resulting in germline tumors and sterility (
Fig. 3E
) (
Berry ., 1997
). Therefore, the aberrant regulation of GLP-1/Notch signaling can cause either loss of germline stem cells or overproliferation of a specific cell type, resulting in sterility.
- Phenotype-based drug discovery for Notch signaling usingglp-1mutants
The
C. elegans
has multiple Notch mutants, including
glp-1
(
q46
) or
glp-1
(
q175
) null mutants,
glp-1
(
bn18 or q224
) temperature-sensitive (ts), loss-of-function (lf) mutants, and
glp-1
(
ar202
) temperature sensitive (ts), gain-of-function (gf) mutant (
Table 1
). In
C. elegans
germline, GLP-1/Notch signaling is essential for germline stem cell maintenance and mitotic germ cell proliferation (
Kimble and Crittenden, 2007
). For example, at 20°C or lower, temperature sensitive, loss-of-function mutants for
glp-1
, “
glp-1(bn18)
and
glp-1(q224)
” produce sperm and oocytes and are therefore fertile (
Fig. 3D
and
3E
left). Conversely, at 25°C, they have a severe proliferation defect and early meiotic entry (
Fig. 3D
right). However, a temperature sensitive, gain-of-function mutant for
glp-1
, “
glp-1(ar202)
” with constitutively active GLP-1/Notch signaling promotes proliferation of germline stem cells and inhibits entry into meiosis, resulting in germline tumors at 25°C (
Fig. 3E
right) (
Pepper ., 2003b
). Notably, this germline tumor phenotype is rescued by the depletion of GLP-1/Notch signaling component genes, including LAG-3/SEL-8/mastermind (
Petcherski and Kimble, 2000
). Therefore,
glp-1(lf)
or
glp-1(gf)
mutants are useful animals for the identification of drugs that may target GLP-1/Notch signaling positively or negatively (
Fig. 3F
). The specificity can be tested by measuring the expression of direct GLP-1/Notch signaling target genes (e.g.,
fbf-2
,
lip-1
,
lst-1
, or
sygl-1
) (
Lamont ., 2004
;
Lee ., 2006
;
Kershner ., 2014
) or by analyzing the effect of drugs on GLP-1/Notch-unrelated synthetic mutants with germline tumors (e.g.,
gld-3, nos-3
) (
Eckmann ., 2002
). Together,
C. elegans
GLP-1/Notch signaling pathways and their core components are highly conserved in vertebrates, including humans. Therefore, the identification and characterization of such drugs will provide a tremendous promise for cancer therapy.
ONCOGENIC PATHWAYS: RAS SIGNALING
- Overview of Ras signaling pathway
Ras-ERK MAP (Mitogen Activated Protein) kinase (MAPK) signaling pathways are highly conserved in all eukaryotes and are involved in numerous cellular responses including proliferation, differentiation, cell fate specification, cellular homeostasis, and survival (
Fig. 4A
) (
Marshall, 1995
;
Whelan ., 2012
). Extracellular stimuli such as growth hormone activate Ras-ERK MAPK signaling through a MAPK signaling cascade. In short, extracellular ligands bind to the epidermal growth factor receptor (EGFR) and activate tyrosine kinase activity of the cytoplasmic domain of the EGFR (
Fig. 4A
). The EGFR-binding adaptor, Grb2, binds to the phosphotyrosine residues of the activated receptor (
Schulze ., 2005
) and to the guanine nucleotide exchange factor, SOS, through two SH3 domains of GRB2. This Grb2/SOS complex when docked to phosphorylated EGFR is activated, which then promotes the activation of Ras proteins (
Fig. 4A
). Activated Ras phosphorylates and activates RAF kinase, activated RAF phosphorylates and activates MEK, and activated MEK phosphorylates and activates ERK MAPK (
Fig. 4A
). Finally, activated ERK MAPK regulates its downstream targets in the positive or negative manners by phosphorylation (
Fig. 4A
). The downstream targets include transcription regulators (e.g., GATA-1) (
Towatari ., 2004
), translational regulators (e.g., p90 ribosomal S6 kinases: RSK1, 2, 3) (
Zhao ., 1996
), cell cycle regulators (e.g., Cyclin D1) (
Okabe ., 2006
), and apoptosis regulators (e.g., BCL-2) (
Tamura ., 2004
). Therefore, aberrant activation of Ras-ERK MAPK signaling contributes to abnormal gene expression, cell cycle progression, proliferation, and survival. Notably, a constitutively active Ras-ERK MAPK signaling has been shown to lead to the development of all cancers (
Saxena ., 2008
). Therefore, the drugs that target Ras-ERK MAPK signaling are potential drugs for treating cancer.
- Ras signaling and cancer stem cells
The Ras-ERK MAPK signaling pathway governs many cellular processes in most animals and is deregulated in approximately one-third of all human cancers. Because of its importance in cancer, the Ras-ERK MAPK signaling pathway has been an attractive target for anti-cancer therapy. For example, Moon
et al
examined the role of two genes,
APC
and
K-Ras
, working in tandem in initiating colorectal cancer progression (
Moon ., 2014
). The group’s data showed that a gain-of-function mutation of the oncogenic
K-Ras
, fixing it in the active, GTP-bound conformation, accelerates the ERK pathway, which in turn activates the Wnt/β-catenin pathway, inducing cancer stem cell marker expression in colorectal cancer cells (
Moon ., 2014
). Increased contribution to tumorigenesis and liver metastasis in
K-Ras
(
gf
) was observed in the presence of loss-of-function mutations in adenomatous polyposis coli (
APC
), a negative regulator of β-catenin concentration, another condition characteristic of initial and intermediate stage colorectal cancer (
Moon ., 2014
). The study utilized specimens from human colorectal cancer patients and
APCMin/+/K-RasLA2
mice, which were studied for their ability to form spheroids
in vitro
and tumors
in vivo
, respectively. A mouse xenograft model was also utilized using wild-type
K
-Ras and mutant
K
-Ras cells to observe cancer stem cell activation as a result of
K
-Ras mutation. Therefore, Ras activation can initiate the formation of cancer stem cells through Wnt/β-catenin activation.
- C. elegansRas signaling
The Ras-ERK MAPK signaling pathways governs many cellular processes, including proliferation, differentiation, cell fate specification, homeostasis, and survival in all eukaryotes. The Ras-ERK MAPK signaling pathways in the
C. elegans
germline are well described by Sundaram (
Sundaram, 2006
). Notably, core signaling pathways and their components are strikingly conserved (
Fig. 4B
) (
Sundaram, 2006
;
Whelan ., 2012
). Briefly, two different RTKs, LET-23 (an EGFR homolog) and EGL-15 (a FGFR homolog) stimulate LET-60 (a Ras homolog) and its downstream cascade, consisting of LIN-45 (a Raf homolog), MEK2 (an MEK homolog) and MPK-1 (an ERK homolog) (
Fig. 4B
). This
C. elegans
Ras-ERK MAPK signaling controls multiple developmental events, including meiotic cycle progression, oocyte activation, sperm fate specification, spermatogenesis, physiological apoptosis, axon guidance, and vulva development (
Lee ., 2006
;
Sundaram, 2006
;
Lee ., 2007b
;
Morgan ., 2010
) (
Fig. 4B
). In wild-type
C. elegans
hermaphrodite germline, activated MPK-1/ERK was not detected in the distal germline (e.g., germline stem cell region and pre-meiotic region) but became abundant in the proximal part of the pachytene region and in maturing oocytes (
Lee ., 2007a
;
Lee ., 2007b
) (
Fig. 4C
). Activated MPK-1/ERK is subject to two redundant modes of downregulation in the germline stem cell region: FBF-1/-2 (members of PUF RNA-binding protein family) proteins act post-transcriptionally to repress
mpk-1/ERK
mRNA and LIP-1 acts post-translationally to inhibit MPK-1/ERK activity (
Fig. 4C
) (
Lee ., 2007a
). This regulation is also conserved in human embryonic stem cells (
Lee ., 2007a
;
Whelan ., 2012
). Therefore, the dual negative regulation of MAPK/ERK by both PUF repression and MKP (MAPK phosphatase) inhibition may be a conserved mechanism that influences both stem cell maintenance and possibly tumor progression (
Whelan ., 2012
). In
C. elegans
germline, additional regulators have also been identified as inhibitors of
C. elegans
Ras-ERK MAPK signaling: LARP-1 (La-related protein) and Insulin signaling inhibit Ras-ERK MAPK signaling during oogenesis (
Nykamp ., 2008
;
Lopez ., 2013
). PUF-8 (a member of PUF protein family) represses
let-60/Ras
mRNA expression in the germline stem cell region (
Vaid ., 2013
). The germline center kinase (GCK1) also represses apoptosis by inhibiting Ras-ERK MAPK signaling (
Schouest ., 2009
). Therefore, the Ras-ERK MAPK signaling is regulated positively or negatively by several regulators, including kinases, phosphatases, or RNA regulators.
- Phenotype-based drug discovery for Ras signaling usingmpk-1orpuf-8;lip-1mutants
Loss of Ras-ERK MAPK signaling results in germline sterility due to abnormal meiotic progression and gametogenesis (
Lee ., 2007b
). Intriguingly, this sterility phenotype was rescued by the inhibition of negative Ras-ERK MAPK regulators (e.g., LIP-1) (
Hajnal and Berset, 2002
;
Lee ., 2006
). In contrast, aberrant activation of Ras-ERK MAPK by removal of PUF-8 and LIP-1 promotes sperm fate at 20°C (
Morgan ., 2010
) and induces germline tumors at 25°C (
Cha ., 2012
). For example, a temperature sensitive,
mpk-1
(
ga111
) loss-of-function mutant is mostly fertile at 20°C, but it is sterile at 25°C due to pachytene arrest (
Fig. 4D
). This sterile phenotype is rescued by the depletion of MPK-1 inhibitors (e.g., LIP-1) (
Hajnal and Berset, 2002
;
Lee ., 2006
). In addition, activated MPK-1/ERK in
puf-8
;
lip-1
mutant promotes spermatogenesis without switching into oogenesis (Masculinization of germline (Mog) phenotype) at 20°C and develops germline tumors via dedifferentiation of spermatocytes at 25°C (
Fig. 4E
) (
Morgan ., 2010
;
Cha ., 2012
;
Datla ., 2014
). Surprisingly, inhibition of Ras-ERK MAPK signaling by either genetic mutation or drug treatment (e.g., U0126) sufficiently rescued
puf-8
;
lip-1
sterility (
Morgan ., 2010
;
Cha ., 2012
;
Datla ., 2014
). Therefore,
mpk-1(lf)
mutants and
puf-8
;
lip-1
mutants (
Table 1
) are useful animals for the identification of drugs that may target Ras-ERK MAPK signaling positively or negatively (
Fig. 4F
). The specificity can be confirmed using
let-60(n1046)
gain-of-function mutant or a transgenic worm expressing LET-23 chimeras in which the TK domain was replaced with the human mutant TK domain (L858R or T790M-L858R). Both animals with hyperactive Ras-ERK MAPK signaling in somatic vulva precursor cells induce a multivulva (Muv) phenotype. Notably, these muv phenotypes were rescued by the treatment of Ras-ERK MAPK inhibitors, including AG1478 (an EGFR-TK inhibitor), U0126 (a MEK inhibitor), Gefitinib, Manumycin, and Gliotoxin (
Hara and Han, 1995
;
Bae ., 2012
). Therefore, mutants and transgenic animals are a model system that can be used in signaling or mutation-specific screens for new anti-cancer drugs.
FERTILITY-BASED IN VIVO HIGH-THROUGHPUT DRUG SCREENING AND DRUG TARGET IDENTIFICATION
For large-scale high-throughput drug screening, we have recently developed a fertility and image-based, label-free high-throughput workflow (
Benson ., 2014
). This automated high-content assay enables effect sorting of
C. elegans
mutants into a 384-well plate using the COPAS
TM
Worm Sorter and rapidly measuring either fertility or sterility by scoring the number of viable progeny in wells (
Benson ., 2014
). For example, homozygote mutants for
puf-8
;
lip-1
are sterile and must be maintained as heterozygotes using a GFP-tagged balancer chromosome for chromosome II (e.g.,
mIn[mIs14(Pmyo-2::GFP) dpy-10(e128)
, called
mc6g
). Homozygotes for experiments are typically selected by picking GFP-negative mutants using a fluorescence microscope. However, for large-scale animal handling, it would be advantageous to automatically identify homozygote mutants using a fluorescent marker. To this end, we generated a
puf-8/mc6g; lip-1/lip-1; [Pmyo-2::mCherry]
transgenic mutant strain expressing a red-fluorescent protein, mCherry, in the head (
Fig. 5A
). The incorporation of the red-head marker, allows effective isolation of homozygote
puf-8
;
lip-1
mutants [GFP(−) and mCherry(+)] using an automatic worm sorter, COPAS
TM
BIOSORT
. Furthermore, the mCherry head marker also simplifies detection of
puf-8
;
lip-1
progeny that is difficult to identify using bright field optics (
Fig. 5A
). For fertility and image-based high-throughput drug screening, mutants of Wnt, Notch, or Ras signaling pathways can be incorporated with the red-head marker (mCherry), which allows to measure automatically either fertility or sterility by scoring the number of viable progeny in wells using Arrayscan V
ti
/SpotDetector (
Benson ., 2014
). Detail methods are described in Benson
et al
(
Benson ., 2014
).
To date, several drugs that target core components of each oncogenic signaling pathways through target-specific
in vitro
screening. Nontheless, the drugs also alter normal signaling pathways. Moreover, current affinity-based target identification approaches require each drug of interest to be immobilized to a bead or another affinity- or fluorescent- or radioactive-“tag” so that the target protein can be “pulled down”. However, the coupling of compounds to beads and other molecules could lead to alteration or loss of compound bioactivity and binding. Furthermore, these techniques are time-consuming and require extensive biochemistry or medicinal chemistry expertise (
Lomenick ., 2009
;
Lomenick ., 2011
). Recently, Huang and colleagues reported that the molecular target of the identified drug could be identified using a newly developed technique, called Drug Affinity Responsive Target Stability (DARTS) (
Fig. 5B
) (
Lomenick ., 2009
;
Lomenick ., 2011
). DARTS takes advantage of the concept that protease susceptibility of the target protein is reduced upon drug binding (
Lomenick ., 2009
;
Lomenick ., 2011
). The advantage of this approach is that it is universally applicable as modification of the drug is not necessary and is independent of the mechanism of drug action. In particular, The DARTS is useful for the initial identification of the targets of compounds, but can also be useful for validation of potential protein-ligand interaction (
Lomenick ., 2011
). To test whether the DARTS is useful for molecular target identification of the identified drugs, we established an
in vitro
DARTS technique using a purified GST-tagged human MEK2 (hMEK2) protein with U0126, a well-known MEK2 inhibitor (
Duncia ., 1998
;
Favata ., 1998
) and DMSO (control) (
Fig. 5C
). Interestingly, U0126 (1 uM) stabilized MEK2 protein, thereby reducing protease (pronase) sensitivity of the MEK2 protein (
Fig. 5C
). Although DARTS is a suitable and feasible method to identify the oncogenic target of the drugs, it remains still a major challenge if this method can be applied for all drug targets.
CONCLUSIONS
In this review, we describe three conserved oncogenic signaling pathways that are often associated with the development of cancer stem cells. Importantly, these signaling pathways are highly conserved and critical for germline development in
C. elegans
. Therefore, aberrant regulations of these signaling pathways cause either partially or completely sterile. Notably, inhibition or activation of these signaling pathways by drug treatment retains fertility (
Morgan ., 2010
;
Benson ., 2014
). Based on this finding, we here propose possible phenotype-based high-throughput screening methods to identify drugs that may alter oncogenic signaling pathways. The identification of drugs is a powerful tool of biological analysis and therapeutics as well as can lead to the development of new drugs. However, a critical bottleneck is generating useful drug tools is target identification. Current target identification techniques have several limitations. For example, affinity-based target identification is limited by the necessary to modify each individual without losing bioactivity, and non-affinity-based approaches depend on the drug’s ability to induce specific biochemical or cellular readouts (
Lomenick ., 2009
;
Lomenick ., 2011
). Recently, Huang and colleagues established DARTS as a new technique (
Lomenick ., 2009
;
Lomenick ., 2011
). This technique is able to identify the targets of drugs based on the principle that when a drug binds to a protein, the interaction stabilizes the target protein’s structure, resulting in proteolytic resistance (
Lomenick ., 2009
;
Lomenick ., 2011
). If the specific targets of drugs are identified by DARTS technique, the peptides can be identified by mass-spectrometry after trypsin digestion. Therefore, these approaches, described in this review, have great potential for finding new drugs and will also aid research in cancer therapies.
C. elegans
has also emerged as an attractive model system for functional analyses of bioactive compounds (e.g., nicotine) and natural components. Previously, Xu and colleagues developed a
C. elegans
model of nicotine-dependent behavior (
Feng ., 2006
). They showed that
C. elegans
displays acute and chronic behavioral responses through nAChRs (nicotinic acetylcholine receptor,
acr-5
and
acr-15
in
C. elegans
) that are known to be critical for nicotine dependence in mammals (
Feng ., 2006
;
Sellings ., 2013
). In addition, chronic nicotine exposure can alter the expression of microRNAs and genes that are implicated in reproduction, cholinergic signaling and stress responses (
Smith ., 2013
;
Taki ., 2014
). Kim and colleagues have also reported the effect of the isolated 1,2,3,4,6-penta-O-galloyl-b-D-glucose (PGG) from Curcuma longa L. on longevity using
C. elegans
as a model system (
Ahn ., 2013
). Notably, they demonstrated that PGG reduced intracellular ROS (Reactive Oxygen Species) accumulation through elevated SOD (Superoxide Dismutase).
C. elegans
has been used for the discoveries of antimicrobial drugs (
Ewbank and Zugasti, 2011
;
Squiban and Kurz, 2011
), antifungal drugs (
Anastassopoulou ., 2011
), and Alzheimer’s disease drugs (
Lublin and Link, 2013
). Therefore,
C. elegans
provides a tremendous promise for the discovery of new disease or target-specific drugs, and studying the action mechanism of the newly identified or known drugs (or small-molecules) in a live animal.
Acknowledgements
We thank the members of the Lee laboratory (Specifically Dr. Kwon), Dr. Ruiz-Echevarría, and Dr. Yang for helpful discussion. This work was supported in part by Research and Education Fund, Summer Biomedical Research Program for undergraduates, Oncology Internal Grant, and Brody Bridge Grant from Brody School of Medicine at East Carolina University to M.H.L. RTI University Collaboration Fund to M.H.L and X.P.
Figures and Table
C. elegans and conserved signaling pathways. (A) An adult wild-type (N2) hermaphrodite stained with DAPI (4′,6-diamidino-2-phenylindole). The hermaphrodite has two gonadal tubes. They produce both sperm and oocytes, and are therefore self-fertile (see embryos). (B) A dissected adult hermaphrodite germline stained with DAPI. In the distal end, somatic gonadal cell, called DTC (see dotted red circle), acts as a germline stem cell niche that is essential for germline stem cell maintenance. The DTC fate is specified at least in part by Wnt/β-catenin signaling in early larval stage (L1). In the distal mitotic region (see dotted yellow lines), GLP-1/Notch signaling maintains germline stem cell self-renewal and promotes mitotic cell cycle of progenitor cells. Once mitotic cells enter meiotic cell cycle, Ras-ERK MAPK signaling promotes meiotic germ cell progression (see dotted green lines), pachytene exit (see dotted yellow lines), oocyte maturation (see dotted pink lines; circle, oocyte nuclei) and sperm (see dotted blue lines) fate specification. (C) Schematic of an adult C. elegans hermaphrodite gonad. Somatic DTC is located at the distal end. Cells at the distal end of the germline, including germline stem cells, divide mitotically (yellow). As cells move proximally, they enter meiosis (green) and differentiate into either sperm (blue) or oocytes (pink).
Wnt/β-catenin signaling pathways and a strategy for the phenotype-based drug identification using C. elegans mutants. (A) Without signaling (absence of ligand), negative regulators (CKIα, GSK3β, Axin, and APC) phosphorylate β-catenin, and then ubiquitinated and degraded by the proteasome. (B) With signaling (presence of ligand), stabilized β-catenin in cytoplasm is translocated into nucleus and activate the expression of target genes. (C) Genetic pathway for control DTC fate specification (see text for explanation). (D) Wild-type hermaphrodite has two DTCs. lag-2::GFP reporter is strongly expressed in DTCs (see green). (E) Loss of Wnt/β-catenin signaling affects DTC fate specification. (F) Activation of Wnt/β-catenin signaling contributes to extra DTC formation. (G) Strategy for the phenotype-based identification of drugs that either inhibit or activate Wnt/β-catenin signaling using C. elegans mutants.
Notch signaling pathways and a strategy for the phenotype-based drug identification using C. elegans mutants. (A) Without signaling, negative regulators inhibit the expression of Notch target genes. (B) With signaling, cleaved NICD transports from membrane to nucleus. In nucleus, NICD form a ternary complex with CSL and co-activator, mastermine-like protein, to activate the expression of target genes. (C) C. elegans GLP-1/Notch signaling pathways. The DTC expresses GLP-1/Notch ligands (e.g., LAG-2) and employs GLP-1/Notch signaling to promote continued mitotic divisions. (D) In mutants lacking any of the core elements of the GLP-1/Notch signaling pathways (e.g., glp-1 loss-of-function mutant), germ cells leave the mitotic cell cycle, enter meiosis, and undergo gametogenesis, resulting in no germline stem cells and sterility. Most temperature-sensitive glp-1(bn18) loss-of-function mutants are fertile at 20°C, but they are sterile at 25°C. (E) Constitutively active GLP-1/Notch signaling develop germline tumors. Most temperature-sensitive glp-1(ar202) gain-of-function mutants are fertile at 20°C, but they are sterile due to germline tumors at 25°C. (F) Strategy for the phenotype-based identification of drugs that either inhibit or activate Notch signaling using C. elegans mutants.
Ras signaling pathways and a strategy for the phenotype-based drug identification using C. elegans mutants. (A) Conserved Ras-ERK MAPK signaling pathways. (B) C. elegans Ras-ERK MAPK signaling pathway. (C) Schematic of adult wild-type hermaphrodite germline. MPK-1/ERK is activated in the proximal pachytene and developing oocytes (see red). In the distal germline, FBF-1/-2 and LIP-1 repress MPK-1/ERK activation at the post-transcriptional and translational levels (Lee et al., 2007a). (D) The germline phenotype of temperature-sensitive mpk-1(ga111) loss-of-function mutant. At 20°C, most mpk-1(ga111) mutants are fertile, but they are sterile due to pachytene arrest at 25°C. DAPI staining shows normal pachytene cells (left) and arrested pachytene cells (right). (E) The germline phenotype of puf-8; lip-1 homozygote mutant at 20°C (left) and 25°C (right). The puf-8; lip-1 mutants produce only sperm (Mog phenotype) at 20°C, but spermatocytes are dedifferentiated into mitotically dividing cells, resulting in germline tumors at 25°C. (F) Strategy for the phenotype-based identification of drugs that either inhibit or activate Ras-ERK MAPK signaling using C. elegans mutants.
Fertility and image-based high-throughput screening and In vitro DARTS using human MEK2 (hMEK2). (A) Fertility and image-based high-throughput drug screening. Slightly modified from (Benson et al., 2014). Fluorescence images can be taken on the Arrayscan Vti/SpotDetector can identify numerous progeny in wells treated with drugs and DMSO control. (B) Scheme of DARTS. (C) U0126 protects hMEK2 from pronase degradation. In vitro DARTS technique was optimized using a purified GST-tagged human MEK2 (hMEK2) protein with U0126, a well-known MEK2 inhibitor and DMSO. U0126 stabilizes hMEK2 from 0.001 mg pronase.
Summary of oncogenic signaling pathways and mutant phenotypes
Signaling pathway | Mutants or transgenic lines | Phenotypes | Reference |
---|
Wnt/β-catenin signaling | pop-1(q645) | DTC loss (100%) and sterile | (Siegfried and Kimble, 2002) |
sys-1(q544) | DTC loss (100%) and sterile | (Kidd et al., 2005) |
lin-17(n671) | DTC loss (<10%) and partially sterile | (Phillips et al., 2007) |
ceh-22(q632) | DTC loss (∼40%) and partially sterile | (Lam et al., 2006) |
hs::sys-1 | Extra DTCs and fertile | (Kidd et al., 2005) |
hs::ceh-22 | Extra DTCs and fertile | (Lam et al., 2006) |
GLP-1/Notch signaling | glp-1(q46) | No GSCs (“Glp” phenotype) | (Austin and Kimble, 1987) |
glp-1(bn18)ts | Fertile at 20°C | (Nadarajan et al., 2009) |
glp-1(q224)ts | “Glp” phenotype at 25°C | (Maine and Kimble, 1989) |
glp-1(ar202)ts | Fertile at 20°C | (Pepper et al., 2003a) |
| Germline tumors at 25°C | |
Ras-ERK MAPK signaling | mpk-1(ga117) | Pachytene arrest and sterile | (Lackner and Kim, 1998) |
mpk-1(ga111)ts | Pachytene arrest and sterile at 25°C | (Lackner and Kim, 1998) |
let-60(n1046) | Multi-layered small oocytes and Multivulva (Muv) phenotype | (Hajnal and Berset, 2002)(Beitel et al., 1990) |
puf-8(q725); lip-1(zh15) | Mog sterile at 20°C | (Morgan et al., 2010) |
| Germline tumors at 25°C | (Cha et al., 2012) |
Abel EV
,
Kim EJ
,
Wu J
,
Hynes M
,
Bednar F
,
Proctor E
,
Wang L
,
Dziubinski ML
,
Simeone DM
2014
The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer
PLoS One
9
e91983 -
Ahn D
,
Cha DS
,
Lee EB
,
Kim BJ
,
Lee SY
,
Jeon H
,
Ahn MS
,
Lim HW
,
Lee HY
,
Kim DK
2013
The longevity properties of 1,2,3,4,6-Penta-O-Galloyl-beta-D-Glucose fromCurcuma longainCaenorhabditis elegans
Biomol Ther
21
442 -
446
Allenspach EJ
,
Maillard I
,
Aster JC
,
Pear WS
2002
Notch signaling in cancer
Cancer Biol Ther
1
466 -
476
Anastassopoulou CG
,
Fuchs BB
,
Mylonakis E
2011
Caenorhabditis elegans-based model systems for antifungal drug discovery
Curr Pharm Des
17
1225 -
1233
Artavanis-Tsakonas S
,
Rand MD
,
Lake RJ
1999
Notch signaling: cell fate control and signal integration in development
Science
284
770 -
776
Austin J
,
Kimble J
1987
glp-1 is required in the germ line for regulation of the decision between mitosis and meiosis inC. elegans
Cell
51
589 -
599
Avila JL
,
Kissil JL
2013
Notch signaling in pancreatic cancer: oncogene or tumor suppressor?
Trends Mol Med
19
320 -
327
Bae YK
,
Sung JY
,
Kim YN
,
Kim S
,
Hong KM
,
Kim HT
,
Choi MS
,
Kwon JY
,
Shim J
2012
An in vivoC. elegansmodel system for screening EGFR-inhibiting anti-cancer drugs
PLoS One
7
e42441 -
Bao B
,
Wang Z
,
Ali S
,
Kong D
,
Li Y
,
Ahmad A
,
Banerjee S
,
Azmi AS
,
Miele L
,
Sarkar FH
2011
Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells
Cancer Lett
307
26 -
36
Beitel GJ
,
Clark SG
,
Horvitz HR
1990
Caenorhabditis elegansras gene let-60 acts as a switch in the pathway of vulval induction
Nature
348
503 -
509
Benson JA
,
Cummings EE
,
O’Reilly LP
,
Lee MH
,
Pak SC
2014
A high-content assay for identifying small molecules that reprogramC. elegansgerm cell fate
Methods
68
529 -
535
Berry LW
,
Westlund B
,
Schedl T
1997
Germ-line tumor formation caused by activation of glp-1, aCaenorhabditis elegansmember of the Notch family of receptors
Development
124
925 -
936
Berset T
,
Hoier EF
,
Battu G
,
Canevascini S
,
Hajnal A
2001
Notch inhibition of RAS signaling through MAP kinase phosphatase LIP-1 duringC. elegansvulval development
Science
291
1055 -
1058
Birchmeier W
2011
Stem cells: Orphan receptors find a home
Nature
476
287 -
288
Blelloch R
,
Anna-Arriola SS
,
Gao D
,
Li Y
,
Hodgkin J
,
Kimble J
1999
The gon-1 gene is required for gonadal morphogenesis inCaenorhabditis elegans
Dev Biol
216
382 -
393
Blelloch R
,
Kimble J
1999
Control of organ shape by a secreted metalloprotease in the nematodeCaenorhabditis elegans
Nature
399
586 -
590
Byrd DT
,
Kimble J
2009
Scratching the niche that controlsCaenorhabditis elegansgermline stem cells
Semin Cell Dev Biol
20
1107 -
1113
Byrd DT
,
Knobel K
,
Affeldt K
,
Crittenden SL
,
Kimble J
2014
A DTC niche plexus surrounds the germline stem cell pool inCaenorhabditis elegans
PloS One
9
e88372 -
Cha DS
,
Datla US
,
Hollis SE
,
Kimble J
,
Lee MH
2012
The Ras-ERK MAPK regulatory network controls dedifferentiation inCaenorhabditis elegansgermline
Biochim Biophys Acta
1823
1847 -
1855
Chamorro MN
,
Schwartz DR
,
Vonica A
,
Brivanlou AH
,
Cho KR
,
Varmus HE
2005
FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development
EMBO J
24
73 -
84
Chen PH
,
Chen X
,
Lin Z
,
Fang D
,
He X
2013
The structural basis of R-spondin recognition by LGR5 and RNF43
Genes Dev
27
1345 -
1350
Datla US
,
Scovill NC
,
Brokamp AJ
,
Kim E
,
Asch AS
,
Lee MH
2014
Role of PUF-8/PUF protein in stem cell control, sperm-oocyte decision and cell fate reprogramming
J Cell Physiol
229
1306 -
1311
Duncia JV
,
Santella JB
,
Higley CA
,
Pitts WJ
,
Wityak J
,
Frietze WE
,
Rankin FW
,
Sun JH
,
Earl RA
,
Tabaka AC
,
Teleha CA
,
Blom KF
,
Favata MF
,
Manos EJ
,
Daulerio AJ
,
Stradley DA
,
Horiuchi K
,
Copeland RA
,
Scherle PA
,
Trzaskos JM
,
Magolda RL
,
Trainor GL
,
Wexler RR
,
Hobbs FW
,
Olson RE
1998
MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products
Bioorg Med Chem Lett
8
2839 -
2844
Eckmann CR
,
Kraemer B
,
Wickens M
,
Kimble J
2002
GLD-3, a bicaudal-C homolog that inhibits FBF to control germline sex determination inC. elegans
Dev Cell
3
697 -
710
Eisenmann DM
2005
Wnt signaling
WormBook
1 -
17
Ewbank JJ
,
Zugasti O
2011
C. elegans: model host and tool for antimicrobial drug discovery
Dis Model Mech
4
300 -
304
Fan X
,
Matsui W
,
Khaki L
,
Stearns D
,
Chun J
,
Li YM
,
Eberhart CG
2006
Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors
Cancer Res
66
7445 -
7452
Favata MF
,
Horiuchi KY
,
Manos EJ
,
Daulerio AJ
,
Stradley DA
,
Feeser WS
,
Van Dyk DE
,
Pitts WJ
,
Earl RA
,
Hobbs F
,
Copeland RA
,
Magolda RL
,
Scherle PA
,
Trzaskos JM
1998
Identification of a novel inhibitor of mitogen-activated protein kinase kinase
J Biol Chem
273
18623 -
18632
Feng Z
,
Li W
,
Ward A
,
Piggott BJ
,
Larkspur ER
,
Sternberg PW
,
Xu XZ
2006
AC. elegansmodel of nicotine-dependent behavior: regulation by TRP-family channels
Cell
127
621 -
633
Ferrando AA
2009
The role of NOTCH1 signaling in T-ALL
Hematology Am Soc Hematol Educ Program
353 -
361
Galluzzo P
,
Bocchetta M
2011
Notch signaling in lung cancer
Expert Rev Anticancer Ther
11
533 -
540
Greenwald I
2005
LIN-12/Notch signaling inC. elegans
Worm-Book
1 -
16
Hajnal A
,
Berset T
2002
TheC. elegansMAPK phosphatase LIP-1 is required for the G(2)/M meiotic arrest of developing oocytes
EMBO J
21
4317 -
4326
Hara M
,
Han M
1995
Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation inCaenorhabditis elegans
Proc Natl Acad Sci USA
92
3333 -
3337
He TC
,
Sparks AB
,
Rago C
,
Hermeking H
,
Zawel L
,
da Costa LT
,
Morin PJ
,
Vogelstein B
,
Kinzler KW
1998
Identification of c-MYC as a target of the APC pathway
Science
281
1509 -
1512
Henderson ST
,
Gao D
,
Lambie EJ
,
Kimble J
1994
lag-2 may encode a signaling ligand for the GLP-1 and LIN-12 receptors ofC. elegans
Development
120
2913 -
2924
Holland JD
,
Klaus A
,
Garratt AN
,
Birchmeier W
2013
Wnt signaling in stem and cancer stem cells
Curr Opin Cell Biol
25
254 -
264
Hughes DP
2009
How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize
Cancer Treat Res
152
479 -
496
James RG
,
Conrad WH
,
Moon RT
2008
Beta-catenin-independent Wnt pathways: signals, core proteins, and effectors
Methods Mol Biol
468
131 -
144
Katoh M
2008
WNT signaling in stem cell biology and regenerative medicine
Curr Drug Targets
9
565 -
570
Kershner AM
,
Shin H
,
Hansen TJ
,
Kimble J
2014
Discovery of two GLP-1/Notch target genes that account for the role of GLP-1/Notch signaling in stem cell maintenance
Proc Natl Acad Sci USA
111
3739 -
3744
Kidd AR
,
Miskowski JA
,
Siegfried KR
,
Sawa H
,
Kimble J
2005
A beta-catenin identified by functional rather than sequence criteria and its role in Wnt/MAPK signaling
Cell
121
761 -
772
Kimble J
,
Crittenden SL
2005
Germline proliferation and its control
WormBook
1 -
14
Kimble J
,
Crittenden SL
2007
Controls of germline stem cells, entry into meiosis, and the sperm/oocyte decision inCaenorhabditis elegans
Annu Rev Cell Dev Biol
23
405 -
433
Lackner MR
,
Kim SK
1998
Genetic analysis of theCaenorhabditis elegansMAP kinase gene mpk-1
Genetics
150
103 -
117
Lam N
,
Chesney MA
,
Kimble J
2006
Wnt signaling and CEH-22/tinman/Nkx2.5 specify a stem cell niche inC. elegans
Curr Biol
16
287 -
295
Lamont LB
,
Crittenden SL
,
Bernstein D
,
Wickens M
,
Kimble J
2004
FBF-1 and FBF-2 regulate the size of the mitotic region in theC. elegansgermline
Dev Cell
7
697 -
707
Lee MH
,
Cha DS
,
Mamillapalli SS
,
Kwon YC
,
Koo HS
2014
Transgene-mediated co-suppression of DNA topoisomerase-1 gene inCaenorhabditis elegans
Int Biochem Mol Biol
5
11 -
20
Lee MH
,
Hook B
,
Lamont LB
,
Wickens M
,
Kimble J
2006
LIP-1 phosphatase controls the extent of germline proliferation inCaenorhabditis elegans
EMBO J
25
88 -
96
Lee MH
,
Hook B
,
Pan G
,
Kershner AM
,
Merritt C
,
Seydoux G
,
Thomson JA
,
Wickens M
,
Kimble J
2007a
Conserved regulation of MAP kinase expression by PUF RNA-binding proteins
PLoS Genet
3
e233 -
Lee MH
,
Ohmachi M
,
Arur S
,
Nayak S
,
Francis R
,
Church D
,
Lambie E
,
Schedl T
2007b
Multiple functions and dynamic activation of MPK-1 extracellular signal-regulated kinase signaling inCaenorhabditis elegansgermline development
Genetics
177
2039 -
2062
Lino MM
,
Merlo A
,
Boulay JL
2010
Notch signaling in glioblastoma: a developmental drug target?
BMC Med
8
72 -
Liu J
,
Sato C
,
Cerletti M
,
Wagers A
2010
Notch signaling in the regulation of stem cell self-renewal and differentiation
Curr Top Dev Biol
92
367 -
409
Lomenick B
,
Hao R
,
Jonai N
,
Chin RM
,
Aghajan M
,
Warburton S
,
Wang J
,
Wu RP
,
Gomez F
,
Loo JA
,
Wohlschlegel JA
,
Vondriska TM
,
Pelletier J
,
Herschman HR
,
Clardy J
,
Clarke CF
,
Huang J
2009
Target identification using drug affinity responsive target stability (DARTS)
Proc Natl Acad Sci USA
106
21984 -
21989
Lomenick B
,
Jung G
,
Wohlschlegel JA
,
Huang J
2011
Target identification using drug affinity responsive target stability (DARTS)
Curr Protoc Chem Biol
3
163 -
180
Lopez AL
,
Chen J
,
Joo HJ
,
Drake M
,
Shidate M
,
Kseib C
,
Arur S
2013
DAF-2 and ERK couple nutrient availability to meiotic progression duringCaenorhabditis elegansoogenesis
Dev Cell
27
227 -
240
Lublin AL
,
Link CD
2013
Alzheimer’s disease drug discovery: in vivo screening usingCaenorhabditis elegansas a model for beta-amyloid peptide-induced toxicity
Drug Discov Today Technol
10
e115 -
119
Maine EM
,
Kimble J
1989
Identification of genes that interact with glp-1, a gene required for inductive cell interactions inCaenorhabditis elegans
Development
106
133 -
143
Marshall M
1995
Interactions between Ras and Raf: key regulatory proteins in cellular transformation
Mol Reprod Dev
42
493 -
499
Miyamoto S
,
Rosenberg DW
2011
Role of Notch signaling in colon homeostasis and carcinogenesis
Cancer Sci
102
1938 -
1942
Moon BS
,
Jeong WJ
,
Park J
,
Kim TI
,
Min do S
,
Choi KY
2014
Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/beta-catenin signaling
J Natl Cancer Inst
106
djt373 -
Morgan CT
,
Lee MH
,
Kimble J
2010
Chemical reprogramming ofCaenorhabditis elegansgerm cell fate
Nat Chem Biol
6
102 -
104
Nadarajan S
,
Govindan JA
,
McGovern M
,
Hubbard EJ
,
Greenstein D
2009
MSP and GLP-1/Notch signaling coordinately regulate actomyosin-dependent cytoplasmic streaming and oocyte growth inC. elegans
Development
136
2223 -
2234
Nusse R
,
Fuerer C
,
Ching W
,
Harnish K
,
Logan C
,
Zeng A
,
ten Berge D
,
Kalani Y
2008
Wnt signaling and stem cell control
Cold Spring Harb Symp Quant Biol
73
59 -
66
Nykamp K
,
Lee MH
,
Kimble J
2008
C. elegansLa-related protein, LARP-1, localizes to germline P bodies and attenuates Ras-MAPK signaling during oogenesis
RNA
14
1378 -
1389
O’Reilly LP
,
Luke CJ
,
Perlmutter DH
,
Silverman GA
,
Pak SC
2014
C. elegansin high-throughput drug discovery
Adv Drug Deliv Rev
69–70
247 -
253
Okabe H
,
Lee SH
,
Phuchareon J
,
Albertson DG
,
McCormick F
,
Tetsu O
2006
A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation
PLoS One
1
e128 -
Pennica D
,
Swanson TA
,
Welsh JW
,
Roy MA
,
Lawrence DA
,
Lee J
,
Brush J
,
Taneyhill LA
,
Deuel B
,
Lew M
,
Watanabe C
,
Cohen RL
,
Melhem MF
,
Finley GG
,
Quirke P
,
Goddard AD
,
Hillan KJ
,
Gurney AL
,
Botstein D
,
Levine AJ
1998
WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors
Proc Natl Acad Sci USA
95
14717 -
14722
Pepper AS
,
Killian DJ
,
Hubbard EJ
2003a
Genetic analysis ofCaenorhabditis elegansglp-1 mutants suggests receptor interaction or competition
Genetics
163
115 -
132
Pepper AS
,
Lo TW
,
Killian DJ
,
Hall DH
,
Hubbard EJ
2003b
The establishment ofCaenorhabditis elegansgermline pattern is controlled by overlapping proximal and distal somatic gonad signals
Dev Biol
259
336 -
350
Petcherski AG
,
Kimble J
2000
LAG-3 is a putative transcriptional activator in theC. elegansNotch pathway
Nature
405
364 -
368
Phillips BT
,
Kidd AR
,
King R
,
Hardin J
,
Kimble J
2007
Reciprocal asymmetry of SYS-1/beta-catenin and POP-1/TCF controls asymmetric divisions inCaenorhabditis elegans
Proc Natl Acad Sci USA
104
3231 -
3236
Reedijk M
2012
Notch signaling and breast cancer
Adv Exp Med Biol
727
241 -
257
Reya T
,
Clevers H
2005
Wnt signalling in stem cells and cancer
Nature
434
843 -
850
Ristorcelli E
,
Lombardo D
2010
Targeting Notch signaling in pancreatic cancer
Expert Opin Ther Targets
14
541 -
552
Saxena N
,
Lahiri SS
,
Hambarde S
,
Tripathi RP
2008
RAS: target for cancer therapy
Cancer Invest
26
948 -
955
Schouest KR
,
Kurasawa Y
,
Furuta T
,
Hisamoto N
,
Matsumoto K
,
Schumacher JM
2009
The germinal center kinase GCK-1 is a negative regulator of MAP kinase activation and apoptosis in theC. elegansgermline
PLoS One
4
e7450 -
Schulze WX
,
Deng L
,
Mann M
2005
Phosphotyrosine interactome of the ErbB-receptor kinase family
Mol Syst Biol
2005 0008
1
Sellings L
,
Pereira S
,
Qian C
,
Dixon-McDougall T
,
Nowak C
,
Zhao B
,
Tyndale RF
,
van der Kooy D
2013
Nicotine-motivated behavior inCaenorhabditis elegansrequires the nicotinic acetylcholine receptor subunits acr-5 and acr-15
Eur J Neurosci
37
743 -
756
Siegfried KR
,
Kimble J
2002
POP-1 controls axis formation during early gonadogenesis inC. elegans
Development
129
443 -
453
Smith MA
,
Zhang Y
,
Polli JR
,
Wu H
,
Zhang B
,
Xiao P
,
Farwell MA
,
Pan X
2013
Impacts of chronic low-level nicotine exposure onCaenorhabditis elegansreproduction: identification of novel gene targets
Reprod Toxicol
40
69 -
75
Squiban B
,
Kurz CL
2011
C. elegans: an all in one model for antimicrobial drug discovery
Curr Drug Targets
12
967 -
977
Sun W
,
Gaykalova DA
,
Ochs MF
,
Mambo E
,
Arnaoutakis D
,
Liu Y
,
Loyo M
,
Agrawal N
,
Howard J
,
Li R
,
Ahn S
,
Fertig E
,
Sidransky D
,
Houghton J
,
Buddavarapu K
,
Sanford T
,
Choudhary A
,
Darden W
,
Adai A
,
Latham G
,
Bishop J
,
Sharma R
,
Westra WH
,
Hennessey P
,
Chung CH
,
Califano JA
2014
Activation of the NOTCH pathway in head and neck cancer
Cancer Res
74
1091 -
1104
Sundaram MV
2006
RTK/Ras/MAPK signaling
WormBook
1 -
19
Taki FA
,
Pan X
,
Zhang B
2014
Chronic nicotine exposure systemically alters microRNA expression profiles during post-embryonic stages inCaenorhabditis elegans
J Cell Physiol
229
79 -
89
Tamura Y
,
Simizu S
,
Osada H
2004
The phosphorylation status and anti-apoptotic activity of Bcl-2 are regulated by ERK and protein phosphatase 2A on the mitochondria
FEBS Lett
569
249 -
255
Tetsu O
,
McCormick F
1999
Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
Nature
398
422 -
426
Tilmann C
,
Kimble J
2005
Cyclin D regulation of a sexually dimorphic asymmetric cell division
Dev Cell
9
489 -
499
Towatari M
,
Ciro M
,
Ottolenghi S
,
Tsuzuki S
,
Enver T
2004
Involvement of mitogen-activated protein kinase in the cytokine-regulated phosphorylation of transcription factor GATA-1
Hematol J
5
262 -
272
Vaid S
,
Ariz M
,
Chaturbedi A
,
Kumar GA
,
Subramaniam K
2013
PUF-8 negatively regulates RAS/MAPK signalling to promote differentiation ofC. elegansgerm cells
Development
140
1645 -
1654
Visvader JE
,
Lindeman GJ
2012
Cancer stem cells: current status and evolving complexities
Cell stem cell
10
717 -
728
Wang D
,
Huang B
,
Zhang S
,
Yu X
,
Wu W
,
Wang X
2013
Structural basis for R-spondin recognition by LGR4/5/6 receptors
Genes Dev
27
1339 -
1344
Wend P
,
Holland JD
,
Ziebold U
,
Birchmeier W
2010
Wnt signaling in stem and cancer stem cells
Semin Cell Dev Biol
21
855 -
863
Whelan JT
,
Hollis SE
,
Cha DS
,
Asch AS
,
Lee MH
2012
Post-transcriptional regulation of the Ras-ERK/MAPK signaling pathway
J Cell Physiol
227
1235 -
1241
Yoo AS
,
Bais C
,
Greenwald I
2004
Crosstalk between the EGFR and LIN-12/Notch pathways inC. elegansvulval development
Science
303
663 -
666
Zhao Y
,
Bjorbaek C
,
Moller DE
1996
Regulation and interaction of pp90(rsk) isoforms with mitogen-activated protein kinases
J Biol Chem
271
29773 -
29779